' Marginal Benefit ' With Rivaroxaban in Cancer Patients ' Marginal Benefit ' With Rivaroxaban in Cancer Patients

The oral drug rivaroxaban was used for prophylaxis against primary venous thromboembolism in ambulatory cancer patients treated in the outpatient setting.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news